Why Cabaletta Bio (CABA) Is Up 41.3% After FDA Clears Automated CAR T Manufacturing Platforms

Cellares recently announced that Cabaletta Bio’s investigational CAR T therapy rese-cel received FDA clearance of an IND ...
MyChesCo on MSN

Cabaletta targets 2027 FDA filing as autoimmune CAR-T push accelerates

PHILADELPHIA, PA — Cabaletta Bio, Inc. (Nasdaq: CABA) laid out an ambitious 2026 roadmap centered on advancing rese-cel, its ...
Seeking Alpha

Cabaletta Bio Announces 2027 Rese-cel BLA Submission Anticipated in Myositis Following Recent FDA Alignment on Registrational Cohorts

– RMAT designation granted for rese-cel in myositis, which is a disabling, multi-system autoimmune disease affecting approximately 80,000 U.S. patients with no approved treatments other than monthly ...
Nasdaq

Cabaletta Bio Announces Presentations Featuring Updated Clinical Data on Rese-cel at Upcoming Scientific Meetings in February

Session: Session 9: Targeting Non-malignant DiseasesTitle: Clinical and Translational Studies of Rese-cel (an anti-CD19 CAR T Therapy) in Myositis, SLE, and Systemic Sclerosis: RESET Phase I/II ...
Nasdaq

Cabaletta Bio to Present Updated Clinical Data on Rese-cel at 2025 Scientific Conferences

Cabaletta Bio, Inc., a clinical-stage biotechnology company focused on targeted cell therapies for autoimmune diseases, announced that updated clinical data on its investigational therapy, ...
Seeking Alpha

Exclusive BAC Article: Cabaletta Bio; Rese-Cel Myositis Data At Meetings 2nd Half 2025, Two Other Possible Registration Cohorts In 2025 And Catalysts

I believe that a good speculative biotech to go over for the "Exclusive BAC Subscribers Article" would be Cabaletta Bio (CABA). The reason why I want to go over this biotech next is because it has ...